Details
NameSymbolSector
GLAXOSMITHKLINE PHARMACEUTICALS LIMITEDGLAXOPharmaceuticals
Open
3162.9
High
3184.3
Low
2890
Close
2936.5
Volume
282736
Exchange
nse
Time
01/08
Outlook
Score:  

0.25

Rating:  

RISKY

Candlestick Pattern
Candle pattern of Glaxosmithkline Pharmaceuticals:  
Closingmarubozu
Estimated Stoploss of Glaxosmithkline Pharmaceuticals: ₹  
3184.3
Glaxosmithkline Pharmaceuticals has a  
Bearishℹ
 pattern. 
Glaxosmithkline Pharmaceuticals has chances of  
Continuationℹ
 of the current trend. 
Trend
Glaxosmithkline Pharmaceuticals is in  
Downtrendℹ
. 
Price of Glaxosmithkline Pharmaceuticals is  
Downℹ
 by  

8.58

%. 
Target
Buy @ 

2791.7

Sell @ 

3319.9

Volume
The trades of Glaxosmithkline Pharmaceuticals have been in  
Immenseℹ
 volume. 
The volume trades for Glaxosmithkline Pharmaceuticals are  
Bearishℹ
 with  
Strong Sellersℹ
The trade volume of Glaxosmithkline Pharmaceuticals is  

Up

 by  

67.84

% 
Valuation
The current market price of Glaxosmithkline Pharmaceuticals is  
Overvaluedℹ
Financials
Balance
The balance sheet of Glaxosmithkline Pharmaceuticals is:  

Balanced

Income
The income of Glaxosmithkline Pharmaceuticals is  

₹ 1015cr

 and  

Profit

 is :  

₹ 262cr

(*Mar 2025)

Glaxosmithkline Pharmaceuticals Profit is up by:  

14.41

% and Income is Up by:  

3.15

% 

(*Mar 2025)

The income of Glaxosmithkline Pharmaceuticals is  

₹ 984cr

 and  

Profit

 is :  

₹ 229cr

(*Dec 2024)

Glaxosmithkline Pharmaceuticals Profit is down by:  

9.13

% and Income is Down by:  

5.84

% 

(*Dec 2024)

The income of Glaxosmithkline Pharmaceuticals is  

₹ 1045cr

 and  

Profit

 is :  

₹ 252cr

(*Sep 2024)

Glaxosmithkline Pharmaceuticals Profit is up by:  

38.46

% and Income is Up by:  

22.94

% 

(*Sep 2024)

Cashflow
The cash flow of Glaxosmithkline Pharmaceuticals is  
Excellentℹ
. It is  
Upℹ
 by  

1534.48

%. 

(*Mar 2025)

61.29% operatingℹ
2.14% investingℹ
36.57% financingℹ
0% otherℹ
By using this site you agree to the use of cookies to deliver a better site experience.